近日，有着月子中心"爱马仕"之称的圣贝拉正式登陆港交所，上市首日便大涨33.74%，市值最高飙升至53.66亿港元。 不过，在行业人士看来，此次上市更像是孤注一掷。根据财报显示，圣贝拉近年来虽然营收不断上涨，但净利润持续为负，亏损总额当前已来到7.73亿 元，而在巨大的资金压力下，上市成为了松绑的唯一选择。刚好，港交所在2025年5月推出了"科企专线"政策，这让圣贝拉看到了机会，于是将月子中心 与医疗、科技相结合作为估值支撑点，最终得以顺利上市。 | 序号 | 1541 | 企业画像 | 最新上市申请时间 | 上市交易所 | | --- | --- | --- | --- | --- | | 1 | Babycare | 新一代母婴家庭一站式、全品类解决方案商 | 2023年9月 | 上交所 | | 2 | 韦拓生物 | 辅助生殖实验室试剂和耗材 | 2024年3月 | 港交所 | | 3 | 东蕴医疗 | 辅助生殖冷冻及培养技术解决方案提供商 | 2024年6月 | 上交所 | | 4 | 爱维艾夫 | 辅助生殖医疗集团 | 2024年10月 | 港交所 | | ર | 纽曼思健康 | 高端母婴营养食品企业 ...

Core Insights - The establishment of Meituan's Aesthetic Medicine Upstream Brand Advisory Committee marks a significant step in enhancing collaboration with upstream brands in the aesthetic medicine industry [1][2] - The Chinese aesthetic medicine market is projected to grow from 3,093 billion yuan last year to 7,102 billion yuan by 2031, indicating substantial growth potential [1] - The industry faces serious challenges, including a low authenticity rate of aesthetic medicine injectables at only 35%, leading to significant consumer complaints regarding product quality [1] Group 1 - The newly formed advisory committee will serve to strengthen the partnership between Meituan and upstream brands, aiming for strategic collaboration and innovation in the industry [2] - Meituan has deepened its cooperation with over 100 brands this year, with a goal of covering more than 200 brands, thereby enhancing the balance among platforms, brands, institutions, and users [2] - During the recent "618" shopping festival, the number of upstream cooperative brands on Meituan's platform increased by over 110%, with transaction volume growing nearly 150% [2] Group 2 - The advisory committee is expected to set a benchmark for upstream brands, driving innovation and sustainable development within the industry [2] - Meituan's initiative to launch a "Find Brand" channel aims to connect consumers directly with authorized brand institutions and professional doctors, addressing issues related to counterfeit products [1]

Core Viewpoint - The medical beauty business is increasingly attracting attention from major internet companies, with JD Health opening its first offline self-operated medical beauty clinic in Beijing [2][4]. Company Developments - JD Health's first self-operated medical beauty clinic, named "JD Medical Beauty (Yizhuang Store)," has opened in Beijing and is integrated into the JD APP's medical beauty channel [2][8]. - A second clinic, "Guomao Store," is set to open on September 30 [3][15]. - The Yizhuang Store has been in trial operation for over two months, primarily serving JD internal employees before its public launch [10][12]. Competitive Landscape - JD Health and Meituan are competing in the medical beauty sector, with Meituan focusing on being a platform without self-operated clinics, while JD Health adopts a dual approach of self-operation and third-party clinic integration [4][20]. - The entry of internet giants like JD and Meituan is intensifying competition for customer acquisition among downstream medical beauty institutions [6][24]. Service Offerings - The Yizhuang Store offers four main light medical beauty services: skin whitening, water light beauty, wrinkle reduction, and light-based anti-aging [16]. - However, the range of specific medical beauty products available is limited, with popular items like "童颜针" (youthful needle) not yet offered [17]. Pricing Strategy - The pricing for services at JD Medical Beauty (Yizhuang Store) is primarily below 1,000 yuan, but some prices, such as for the black gold DPL facial treatment, are higher than competitors [17]. - Current prices are at internal employee rates, with potential future increases anticipated [17]. Market Dynamics - The competition has led to aggressive pricing strategies among medical beauty institutions, with some institutions resorting to significant discounts to attract customers [21]. - JD's entry into the market is seen as a challenge for smaller clinics lacking traffic sources, raising concerns about their survival in a competitive environment [24]. Industry Trends - New Oxygen, another internet platform, has also entered the offline medical beauty clinic space, having opened 30 self-operated clinics across nine cities since May 2023 [23]. - The overall trend indicates a shift towards online platforms integrating offline services, creating a more competitive landscape for traditional medical beauty institutions [20][24].

注射类医美项目是通过针剂注射方式实现微创美容效果的治疗手段，主要分为透明质酸类、肉毒素 类、胶原蛋白类、再生针剂类、溶脂针类和埋植线类。其中，医美注射类市场一直被透明质酸和肉 毒素二分天下，根据 ISAPS 数据， 2023 年全球注射类项目治疗次数排名中，肉毒素以 887.8 万例 居世界第一，玻尿酸以 556.5 万例居世界第二。此外，再生针剂、胶原蛋白针也是近年来的"明星 项目"，受到市场的狂热追捧。埋植线、溶脂针因技术不成熟、安全风险高等原因市场发展较为缓 慢，合规产品极少。 注射类医美丨研究报告 核心摘要： 技术手段与审美认知共同引领医美行业变革。随着医美行业进入发展期，非手术项目选择逐渐丰富，"抗衰 老"成为消费者的核心诉求。注射类轻医美项目为精细化美容塑型提供技术支持，消费者在"变美"基础上更 加追求"自然"。随着新材料的不断出现、及传统材料的不断创新，注射类医美项目丰富度持续提升，满足多 元审美需求，加之其效果明显、恢复期短、可及性强，复购率不断上涨，案例数及市场规模呈现出超越行业 平均的增速。艾瑞认为，注射类医美市场将成为医美领域新蓝海。 注射类医美概念及分类 通过针剂注射实现微创美容，透明 ...

Core Viewpoint - Jingze Biopharma has submitted an application for listing on the Hong Kong Stock Exchange, focusing on assisted reproductive and ophthalmic drugs, with eight candidate drugs in its pipeline [1][3]. Group 1: Company Overview - Jingze Biopharma aims to commercialize its first product, JZB30, a recombinant human follicle-stimulating hormone (FSH) lyophilized powder injection, expected to generate revenue by 2026 [1][3]. - The company has previously attempted to list on the Shanghai Stock Exchange's Sci-Tech Innovation Board but faced delays in completing the necessary guidance [1][3]. Group 2: Product Pipeline and Market Competition - All of Jingze Biopharma's late-stage products are generic drugs, with JZB30 competing against established products like Follitropin [4][6]. - The domestic market for recombinant human FSH is dominated by companies like Merck and Jinsai Pharmaceutical, which have significant market shares [6][9]. - The market for injectable recombinant human FSH has shown limited growth, with sales fluctuating between 1.12 billion and 2.02 billion from 2015 to 2023 [6][9]. Group 3: Financial Situation - Jingze Biopharma has been operating at a loss, with projected losses of approximately 246 million and 243 million for 2023 and 2024, respectively [9][10]. - The company has raised about 930 million through six rounds of financing, with a significant portion raised during the C+ round [9][10]. - As of the end of 2024, the company's cash reserves were critically low, with only 68.6 million and 27.08 million remaining [10].

二、产成品分析 第三节 2020-2024年中国针剂所属行业销售情况分析 一、销售产值分析 二、产销率情况 第四节 2020-2024年中国针剂所属行业经营效益分析 一、盈利能力分析 二、运营能力分析 三、偿债能力分析 四、发展能力分析 第六章针剂行业竞争态势分析 第一节 针剂行业集中度分析 一、针剂市场集中度分析 二、各区域生产企业相关批文数对比 三、针剂区域消费集中度分析 第二节针剂行业五力竞争分析 一、现有企业间竞争 二、潜在进入者分析 三、替代品威胁分析 四、供应商议价能力 五、客户议价能 第三节 2024年中外针剂产品竞争分析 第四节 近年国内针剂行业重点企业发展动向 第七章2020-2024年中国针剂行业区域发展分析 第一节 中国针剂行业区域发展现状分析 第二节 2020-2024年华北地区 一、地区经济发展现状分析 二、市场规模情况分析 三、行业发展前景预测 第三节 2020-2024年东北地区 第四节 2020-2024年华东地区 共研网发布的《2025-2031年中国针剂行业全景调研及投资战略报告》共十二章。报告首先介绍了针剂 行业定义、商业模式、产业壁垒、风险因素、产业特征及研究方法；接着 ...

6月27日，景泽生物医药（合肥）股份有限公司（简称"景泽生物"）向港交所递交上市申请。 作为生物制药公司，景泽生物布局辅助生殖药物和眼科药物赛道，共拥有八个候选药物。由于尚未有产 品上市销售，2023年、2024年，公司连续两年出现净亏损。 其首款核心产品已获批并即将推进商业化，预计将于2026年产生收入。然而，激烈的市场竞争为其核心 产品的商业化前景增添了不确定性。 拥有8个候选药物 首款产品商业化在即 截至目前，景泽生物拥有八款候选药物，其中三款处于后期研发阶段，一款已获批上市，一款已提交新 药上市申请（NDA），另一款正处于III期临床试验阶段。其中，重组人促卵泡激素(rhFSH)冻干粉针剂 型产品JZB30、抗VEGF（血管内皮生长因子）眼内注射液JZB05为公司的核心产品。 公司即将推进商业化的产品为核心产品JZB30，该产品的NDA已于2025年4月获得国家药监局批准。 作为公司眼科领域首个预期商业化产品，另一款核心产品JZB05主要用于治疗湿性年龄相关性黄斑变性 （wAMD）、糖尿病黄斑水肿（DME）等眼底新生血管性疾病。该产品是对标全球销售额最高眼科药 物、抗VEGF药物阿柏西普的全球生物类似 ...

Core Viewpoint - Jingze Biopharmaceutical (Hefei) Co., Ltd. has submitted its prospectus for an IPO on the Hong Kong Stock Exchange, facing challenges due to significant losses and a reliance on a single approved drug while having multiple candidates in development [1][8]. Group 1: Company Overview - Jingze Biopharmaceutical was established in 2014, focusing on assisted reproduction and ophthalmic drugs, and is one of the leading companies in China for clinical-stage macromolecule drugs in these fields [2][3]. - The company has eight drug candidates, with only one product, JZB30, approved for commercialization in the assisted reproduction sector [3][4]. Group 2: Product Pipeline - JZB30, a recombinant human follicle-stimulating hormone lyophilized powder injection, was approved by the National Medical Products Administration in April 2025, targeting the global ovulation market [3]. - JZB33, a biosimilar to the imported drug Ganirelix, has completed bioequivalence studies and an NDA has been submitted [4]. - In the ophthalmic sector, JZB05, an anti-VEGF intravitreal injection, is in Phase III clinical trials, with an NDA submission expected in the second half of 2026 [4]. Group 3: Financial Performance - Jingze Biopharmaceutical reported losses of CNY 246 million and CNY 243 million for 2023 and 2024, respectively, with R&D expenses of CNY 122 million and CNY 133 million [5]. - As of the end of 2024, the company had cash and cash equivalents of CNY 68.59 million, with net current liabilities increasing to CNY 1.325 billion [5]. Group 4: Funding and Future Plans - The company has raised a total of CNY 927 million through various funding rounds from 2018 to 2023, with a post-investment valuation of CNY 3.09 billion in the C+ round [5]. - The IPO proceeds are intended to advance clinical trials and production development for multiple pipelines [5]. Group 5: Operational Challenges - Jingze Biopharmaceutical relies heavily on third-party contract research organizations (CROs) for preclinical and some clinical trials, which poses risks related to timely delivery and compliance [6]. - The company plans to establish a sales network in collaboration with well-known domestic pharmaceutical companies to distribute JZB30 and has partnered with Nanjing Jianyou for U.S. market registration of JZB33 [6]. Group 6: Market Strategy - The company aims to build a business team to assist partners in market development, although this requires significant time and funding [7]. - The success of the company is highly dependent on the successful development and commercialization of its drug candidates, which are primarily in preclinical or clinical stages [7].

Core Viewpoint - Jingze Biopharmaceutical (Hefei) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CICC and Guoyuan International as joint sponsors [1] Company Overview - Jingze Biopharmaceutical focuses on high-growth sectors of assisted reproductive drugs and ophthalmic drugs, establishing a comprehensive R&D system and commercial-scale production capabilities [4] - The company has developed multiple product pipelines and advanced several high-tech barrier drugs to late clinical and commercialization stages [4] - As of June 20, 2025, Jingze is one of the leading companies in China for clinical-stage macromolecular drugs in the fields of assisted reproduction and ophthalmology [4] Product Pipeline - The company has a rich product pipeline with eight candidate drugs, three of which are in late-stage development, including one that has received NDA approval and another that has submitted NDA [5] - JZB30, the first commercialized product in assisted reproduction, is a recombinant human follicle-stimulating hormone (rhFSH) lyophilized powder injection, targeting the global ovulation induction market [5][6] - JZB05, an anti-VEGF intravitreal injection, is expected to be the first commercialized product in the ophthalmic field, with ongoing Phase III clinical trials [6] Financial Overview - Research and development expenses for 2023 and 2024 are approximately RMB 122.2 million and RMB 133.3 million, respectively [6] - The total loss for the years 2023 and 2024 is approximately RMB 246.2 million and RMB 242.7 million, respectively [7] - Other income and gains for 2023 and 2024 are RMB 9.8 million and RMB 12.4 million, respectively [7]

Core Viewpoint - Jingze Biopharma is pursuing an IPO on the Hong Kong Stock Exchange, focusing on high-growth areas of assisted reproduction and ophthalmic drugs, despite facing significant financial challenges and uncertainties in its development pipeline [1][3]. Company Overview - Jingze Biopharma specializes in assisted reproduction and ophthalmic drugs, with a notable presence in clinical-stage large molecule drugs in China as of June 20, 2025 [3]. - The company’s core product, JZB30 (recombinant human follicle-stimulating hormone lyophilized powder injection), received commercialization approval in April 2025, targeting the leading imported drug in the global ovulation market [3]. - Another key product, JZB33 (recombinant human follicle-stimulating hormone aqueous injection), has completed bioequivalence trials and submitted a New Drug Application (NDA) as of June 2025 [3]. Product Pipeline - Jingze Biopharma has a total of eight drug candidates, with JZB30 approved and JZB33 submitted for NDA. JZB05 (anti-VEGF intravitreal injection) is undergoing Phase III clinical trials across over 40 centers in China, aiming for submission in the second half of 2026 [4]. - The company is also developing JZB32 for symptomatic vitreomacular adhesion, currently in Phase I clinical trials, along with several other products at various stages of development [4]. Financial Performance - Jingze Biopharma has reported net losses of 246 million yuan and 243 million yuan for 2023 and 2024, respectively, totaling over 480 million yuan in losses over two years [4]. - Research and development expenditures for the same period were 122 million yuan and 133 million yuan, accounting for over 70% of total operating expenses [4]. - As of the end of 2024, the company’s net current liabilities reached 1.325 billion yuan, an increase from 948 million yuan at the end of 2023, indicating significant liquidity pressure [4]. Operational Challenges - The company heavily relies on third-party contract research organizations (CROs) for preclinical research and some clinical trials, as well as third-party manufacturers for production, which poses risks related to timely delivery and compliance [5]. - Jingze Biopharma lacks experience in successfully commercializing drugs, planning to collaborate with established domestic pharmaceutical companies for the distribution of JZB30 while also preparing to build its own sales team, which requires substantial investment and time [5].